Clinical trials: Mild Neurocognitive Disorder
Amnestic Mild Cognitive Impairment
mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment
The mSIM study involves developing and conducting feasibility testing of a web-based application that will deliver mobile-based simultaneous exercise and memory skills training program (mSIM) for amnesic Mild Cognitive Impairment…
- Trial name
- mSIM (NCT04185298)
- Testing
- mSIM intervention plus activity monitoring, Activity monitoring
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jennifer Bramen
Alzheimer's Disease
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 78 weeks in the treatment of…
- Trial name
- EPOCH (NCT01739348)
- Testing
- Verubecestat (Part I and Part II), Verubecestat (Part II)
- Volunteers
- 2,211 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease.
- Trial name
- NCT03289143
- Testing
- Semorinemab, [18F]GTP1
- Where
- 133 sites in United States, Australia and 11 more
- Volunteers
- 457 people
- Sponsor
- Genentech, Inc.
Mild Cognitive Impairment
Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II
Background: Subcortical Vascular Dementia (VaD), consequent to deep brain small vessel disease (SVD), is the most frequent form of VaD.
- Trial name
- RehAtt (NCT02033850)
- Testing
- Attention Process Training-II
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Mild Cognitive Impairment, Neuropsychiatric Syndrome
CogT BEEM Study (a tDCS Study)
Co-existing neuropsychiatric symptoms (NPS) in patients with mild cognitive impairment (MCI), especially those worsening over time, are associated with more rapid cognitive and functional decline and a greater risk of Alzheimer's…
- Trial name
- NCT04099524
- Testing
- tDCS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Rochester
Mild Cognitive Impairment (MCI), Depression
Brain Aging and Treatment Response in Geriatric Depression
The proposed project will evaluate the role of neuroimaging biomarkers of brain aging (i.e., neurodegenerative and vascular brain changes) and mild cognitive impairment in the patterns of treatment response to memantine combined…
- Trial name
- NCT01902004
- Testing
- Escitalopram, Memantine
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of California, Los Angeles
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Mild Cognitive Impairment
Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous immunoglobulins (IVIG) could potentially reduce…
- Trial name
- MCI (NCT01300728)
- Testing
- NewGam 10% IVIG
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Sutter Health
Alzheimer Disease
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease.
- Trial name
- REVERSE-SD (NCT03402659)
- Testing
- neflamapimod
- Where
- 38 sites in United States, Czechia and 3 more
- Volunteers
- 161 people
- Sponsor
- EIP Pharma Inc
Alzheimer Disease
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
This study assessed the Hr QoL (Health related Quality of life) of subjects with mild to moderate AD, who received ARICEPT under usual clinical practice.
- Trial name
- QUEST (NCT01089582)
- Testing
- No intervention
- Where
- 29 sites in Greece
- Volunteers
- 628 people
- Sponsor
- Pfizer
Long-Term Memory Decline, Mild Cognitive Impairment
Wayfinding Intervention in High-Fidelity Long-Term Memory
Therapeutic treatment is yet available for declining memory, which is an impairment affecting the quality of life for many older adults and patients with cognitive impairment.
- Trial name
- LABYR (NCT04253587)
- Testing
- LabyrinthVR, Coherence, Tablet
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Mild Cognitive Impairment
SUPPORT-D Intervention for Persons With Alzheimer's Disease and Their Caregivers
The purpose of this research is pilot test a nurse led intervention previously used in patients with pulmonary fibrosis and their caregivers in a new population (persons living with Mild Cognitive Impairment or Alzheimer's…
- Trial name
- NCT05501119
- Testing
- A Program of SUPPORT-D (dementia)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Medical University of South Carolina
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer's Disease
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
This study evaluated the effect of 6 or 12 infusions of different doses of octagam (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in cerebral spinal fluid (CSF) and on the increase of Aβ in…
- Trial name
- NCT00812565
- Testing
- octagam 10%
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Octapharma
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Parkinson's Disease, Mild Cognitive Impairment
Mild Cognitive Impairment in Parkinson's Disease
Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease.
- Trial name
- NCT01519271
- Testing
- Exelon Patch (rivastigmine transdermal system)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00359944
- Testing
- AC-3933, Sugar Pill
- Where
- 34 sites in United States
- Volunteers
- 171 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mild Cognitive Impairment
Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults
Cognitive impairment is also a major risk factor for development of dementia later in life. Findings from the investigators studies suggest that the carotenoids, lutein and zeaxanthin may be important in cognitive function in the…
- Trial name
- NCT01620567
- Testing
- avocado, potato or chickpea
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tufts University
Mild Cognitive Impairment
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities.
- Trial name
- NCT03482167
- Testing
- Niagen®
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Delaware
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001.
- Trial name
- "MAD" (NCT05363293)
- Testing
- AL001
- Where
- 2 sites in United States, Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Alzamend Neuro, Inc.